METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATION-RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New prostate cancer pill enters human testing
Disease control TerminatedThis was an early-stage study to find a safe dose and understand how the body processes a new oral drug called TQB3720. It involved 192 men whose prostate cancer had spread and stopped responding to standard hormone treatments. The main goals were to check for side effects and me…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
Experimental prostate cancer treatments halted in early trial
Disease control TerminatedThis study tested several experimental drug combinations for men with advanced prostate cancer that had spread and stopped responding to standard hormone treatments. The trial aimed to find safe doses and see if these new approaches could help control the cancer. It was terminate…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: Amgen • Aim: Disease control
Last updated Apr 02, 2026 14:57 UTC
-
Early-Stage trial tests re-engineered immune cells against tough prostate cancers
Disease control TerminatedThis early-stage study tested whether a patient's own immune cells could be modified in a lab to recognize and attack advanced prostate cancer. The treatment, called BPX-601, involved collecting a patient's T-cells, engineering them to target a specific marker on cancer cells, an…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Apr 01, 2026 14:41 UTC
-
Targeted drug combo tested for Tough-to-Treat cancers
Disease control TerminatedThis study tested a drug called zenocutuzumab, combined with other cancer medications, for people with two specific advanced cancers. It aimed to see if the combinations could help control tumors in patients with a certain genetic change (NRG1+) in their lung cancer or in men who…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Mar 18, 2026 14:41 UTC
-
New 'T-Cell Engager' drug tested in men with Tough-to-Treat prostate cancer
Disease control TerminatedThis was an early safety study for a new drug called acapatamab, designed to help the body's own immune cells attack advanced prostate cancer. It involved 212 men whose cancer had spread and was no longer responding to standard hormone and chemotherapy treatments. The main goal w…
Matched conditions: METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Amgen • Aim: Disease control
Last updated Feb 19, 2026 14:36 UTC